Stay updated on Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page.

Latest updates to the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page
- CheckyesterdayChange DetectedThe 'Last Update Posted' label on the Study Details page is now displayed as 'Last Update Posted (Estimated)', indicating the timestamp is approximate.SummaryDifference0.1%

- Check8 days agoChange DetectedAdded Florida as a new study location under Locations, replacing the prior Florida Locations entry. Updated Last Update Posted to 2025-12 and revised the page to v3.3.3.SummaryDifference0.5%

- Check16 days agoNo Change Detected
- Check23 days agoNo Change Detected
- Check37 days agoChange DetectedRevision: v3.3.2 was added and Revision: v3.2.0 removed in the page footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check44 days agoChange DetectedFooter branding updates add 'Moffitt Cancer Center Clinical Trials website' and 'Helpful Links Provided by', and a government funding status notice was removed from the page.SummaryDifference0.6%

- Check58 days agoChange DetectedCore study details appear unchanged; no additions or deletions to the main study information were detected. The overall page structure and key fields such as title, conditions, interventions, outcomes, and eligibility remain the same.SummaryDifference0.4%

- Check87 days agoChange DetectedSummary: The page adds a government-operating-status notice and a v3.2.0 release tag, while removing the v3.1.0 tag. The new notice is the significant change, signaling updated operating status and potential transaction delays.SummaryDifference3%

Stay in the know with updates to Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Lenvatinib in Neuroendocrine Tumors Clinical Trial page.